Pembrolizumab continues to demonstrate a disease-free and overall survival benefit for patients with clear cell renal ...
Niraparib plus dostarlimab with definitive cisplatin plus radiotherapy improves some outcomes in patients with locally ...
(HealthDay News) — State health officials fighting measles outbreaks this spring asked the US Centers for Disease Control and Prevention (CDC) for help getting a faster test. The agency took 2 months ...
Socioeconomic disadvantage, disease presentation, and treatment differences are key contributors to rural-urban mortality gap ...
In patients with extensive-stage small cell lung cancer, adding tarlatamab to durvalumab maintenance therapy significantly ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
Nivolumab-ipilimumab prolongs OS compared to nivolumab alone or chemo in MSI-H or dMMR, unresectable or metastatic colorectal ...
The intismeran/pembrolizumab combination significantly improved relapse-free and distant metastasis-free survival in advanced ...
Combining the novel, highly selective HDAC inhibitor HBI-8000 with nivolumab significantly improves PFS in unresectable ...
Updated findings from the OptimUM trials support the use of darovasertib plus crizotinib in the treatment of patients with ...
Combining adjuvant ribociclib with an NSAI improves long-term survival in HR-positive, HER2-negative early breast cancer over ...
Neoadjuvant therapy with trastuzumab deruxtecan is of only “modest” benefit in patients with HER2-low, HR+ early-stage breast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results